Drug legislation and regulation as part of the health care system Valerio Reggi, Eshetu Wondemagegnehu HTP/EDM/QSM - 3 October 2001 1 PAR Seminar, 3
Download ReportTranscript Drug legislation and regulation as part of the health care system Valerio Reggi, Eshetu Wondemagegnehu HTP/EDM/QSM - 3 October 2001 1 PAR Seminar, 3
Drug legislation and regulation as part of the health care system Valerio Reggi, Eshetu Wondemagegnehu HTP/EDM/QSM - 3 October 2001 1 PAR Seminar, 3 October 2002 WHO - EDM Outline of presentation • Rationale for state role • Key elements of legislation • Key elements of regulatory system • Regulation and public health 2 PAR Seminar, 3 October 2002 WHO - EDM Drug legislation and regulation Rationale for state role Key elements of drug legislation Key elements of drug regulatory system Drug regulation and public health 3 PAR Seminar, 3 October 2002 WHO - EDM Rationale for state role Regulation in medicine is 4000 years old Hammurabi's Code of Laws (~ 2000 BCE): physician fees adapted to patient’s status: 215. …a physician …… shall receive ten shekels in money. 216. If the patient be a freed man, he receives five shekels. 217. If the patient be the slave …… two shekels. sanctions for malpractice: 218. If a physician make a large incision with the operating knife and kill the patient or …. … cut out the eye, his hands shall be cut off. 4 PAR Seminar, 3 October 2002 WHO - EDM Rationale for state role Essential state functions in the pharmaceutical sector Essential means that if the public sector is unable to perform these functions, public health goals cannot be achieved and the least privileged part of the population will suffer. 5 PAR Seminar, 3 October 2002 WHO - EDM Rationale for state role Essential state functions in the pharmaceutical sector Policy making, priority setting: Regulation & control: Professional standards: what are the problems? how do we address them? how do we know what we have achieved? what are the rules? are the rules respected? do we need to change rules? who is allowed to do what? Access to drugs: can people use the drugs they need? Information: can people use drugs properly? 6 PAR Seminar, 3 October 2002 WHO - EDM Market failure: Equity: who cares for the poor? Public/private mix Information imbalance: access to and capacity to assess and compare information on quality, safety, efficacy, value for money, appropriateness External benefits: Failure of competition: Market asymmetry: immunizations and treatment of contagious diseases benefit all, if left to market laws alone many will not be immunized or treated who can develop new drugs? who can influence prescription/consumption? who takes the less profitable activities? competition based on product differentiation rather than price who pays does not choose, who chooses does not pay 7 PAR Seminar, 3 October 2002 WHO - EDM Dr. Gro Harlem Brundtland Director General 8 PAR Seminar, 3 October 2002 “…. drugs are a public good and not simply just another commodity: first for their high social value, and then because consumers and prescribers are unable to assess their quality, safety and efficacy.” WHO - EDM Rationale for state role Selection of essential drugs is a two-step process: 1 - market approval of a pharmaceutical product on the basis of efficacy, safety and quality. This regulatory decision defines the availability of the drug in the market. 2 - most public drug procurement schemes have mechanisms to limit procurement or reimbursements to certain drugs. For these decisions an evaluation is necessary, based on a comparison between various drug products and on considerations of “value for money”. 9 PAR Seminar, 3 October 2002 WHO - EDM Rationale for state role The reality (or the paradox) : - only richer countries make use of this second selection step, and therefore enact mechaisms to rationalise consumption and keep expenditure under control, - in poorer countries, where health insurance mechanisms are not fully developed and people pay most drug out of pockets, there ar no adequate mechanisms to protect consumers 10 PAR Seminar, 3 October 2002 WHO - EDM Rationale for state role In industrialized countries regulatory work takes place in an environment characterized by longer-established regulatory traditions. In addition, there is a relatively mature interaction of interests, actions, and views of regulators, industry with different focuses (innovative medicines, generics, OTC products, ‘alternative’ medicines), professionals, patient and consumers groups, and individuals. 11 PAR Seminar, 3 October 2002 WHO - EDM Rationale for state role In developing countries regulation is often less consolidated than in industrialized countries, and the interaction between the different interested parties is not always balanced. In addition, the resources that can be made available for the implementation of regulatory work and control are not always adequate for the task that regulatory authorities are expected to undertake. This puts special responsibility and burden on decision makers and regulatory officials of developing countries. 12 PAR Seminar, 3 October 2002 WHO - EDM Rationale for state role Consequences of weak drug regulatory capacity Irrational consumption and prescription, substandard, counterfeit, harmful, useless drugs on sale 13 PAR Seminar, 3 October 2002 WHO - EDM Drug legislation and regulation Rationale for state role Key elements of drug legislation Key elements of drug regulatory system Drug regulation and public health 14 PAR Seminar, 3 October 2002 WHO - EDM Key elements of drug legislation Purposes of drug legislation Distinguish “permissible” or “lawful” from “impermissible” or “unlawful” Specify rights, duties, powers Provide a legal basis for regulation Specify sanctions and penalties to be imposed upon those who violate legislation or regulations. 15 PAR Seminar, 3 October 2002 WHO - EDM Key elements of drug legislation Scope of drug legislation What products should be regulated What companies/institutions should be regulated What activities should be regulated To what extent should the above be regulated Who should be responsible for regulation What sanctions should apply in case of violations 16 PAR Seminar, 3 October 2002 WHO - EDM Key elements of drug legislation Items of drug legislation (1) Technical aspects (title, date of operation, areas of application/exclusion, relationship to other existing laws, transitional arrangements). Definitions of terms and concepts Statutory powers (right of inspection), duties and responsibilities of the regulatory authority, and its organization and resources Requirement for company and product licensing and duration of validity of licences 17 PAR Seminar, 3 October 2002 WHO - EDM Key elements of drug legislation Items of drug legislation (2) Special issues: e.g. patents, prices, clinical trials, post-marketing surveillance, conflicts of interest, access to information, advertising and promotion Enforcement procedures, penal provisions, and administrative penalties Right of complaint and appeal against regulatory decisions Scope and power of regulation-making (i.e. main text must authorize that additional provisions are made through regulations) 18 PAR Seminar, 3 October 2002 WHO - EDM Key elements of drug legislation Definitions in drug legislation (1) Products subject to legislation: • clear, unambiguous, comprehensive definition of medicinal product: Any substance or pharmaceutical product for human or veterinary use that is intended to modify or explore physiological systems or pathological states for the benefit of the recipient. 19 PAR Seminar, 3 October 2002 WHO - EDM Key elements of drug legislation Definitions in drug legislation (2) “Borderline” products: criteria and attitudes change, new problems arise • • flexibility to enable DRA to cover specific classes of product to be within scope of law public health approach demands claims in promotion/labelling and consumer that perception decide a productperceive is for medicinal (tonics, be food whatif people as a purpose drug should supplements, soaps and shampoos) regulated vitamins, as a drug 20 PAR Seminar, 3 October 2002 WHO - EDM Key elements of drug legislation Definitions in drug legislation (3) The term "medicinal product" must include, at least: pharmaceutical, biological (vaccines, blood products, other biologicals) and herbal products, including traditional medicines (not harvested by traditional medicine practitioners and sold in package form), products known in many countries as "pharmafoods", "nutriceuticals", or "cosmeceuticals" intended for therapeutic use and whether for animal or human use. WHO Expert Committee on Specifications for Pharmaceutical Preparations. 1998, WHO Technical Report Series, No.885 21 PAR Seminar, 3 October 2002 WHO - EDM Key elements of drug legislation Definitions in drug legislation (4) The drug regulatory authority must also determine to what extent it intends to exempt related products, such as diagnostic materials, medical devices, cosmetics, health foods and food supplements from its scope of issuing marketing authorizations. ……... In borderline cases it might be left to the regulatory authority to decide whether a substance or preparation is considered as a medicinal product. WHO Expert Committee on Specifications for Pharmaceutical Preparations. 1998, WHO Technical Report Series, No.885 22 PAR Seminar, 3 October 2002 WHO - EDM Key elements of drug legislation Definitions in drug legislation (5) Activities subject to legislation: The legislation must apply to all institutions and individuals, within both the public and private sectors, that are engaged in, or connected with any aspect of manufacture, promotion, procurement, distribution, sale or supply of medicinal products. WHO Expert Committee on Specifications for Pharmaceutical Preparations. 1998, WHO Technical Report Series, No.885 23 PAR Seminar, 3 October 2002 WHO - EDM Key elements of drug legislation Definitions in drug legislation (6) Statutory powers in legislation: primary responsibility of the national drug regulatory authority is to operate a system of administration and enforcement intended to achieve the objectives of the legislation WHO Expert Committee on Specifications for Pharmaceutical Preparations. 1998, WHO Technical Report Series, No.885 24 PAR Seminar, 3 October 2002 WHO - EDM Key elements of drug legislation Definitions in drug legislation (7) Statutory powers in legislation: A department of veterinary services or a department dealing with traditional medicine practices may exert administrative oversight of services without exercising regulatory control over the products used within the specific discipline. ……… ensure close and effective coordination between all concerned parties. WHO Expert Committee on Specifications for Pharmaceutical Preparations. 1998, WHO Technical Report Series, No.885 25 PAR Seminar, 3 October 2002 WHO - EDM Drug legislation and regulation Rationale for state role Key elements of drug legislation Key elements of drug regulatory system Drug regulation and public health 26 PAR Seminar, 3 October 2002 WHO - EDM Key elements of drug regulatory system Drug regulation comprises all the legal, administrative & technical arrangements meant to ensure that: all premises, persons & practices engaged in the development, manufacture, importation, exportation, wholesale, supply, dispensing & promotion of drugs comply with approved standards, norms, procedures and requirements drug products are safe, effective and of acceptable quality product information is unbiased, accurate and appropriate drugs are available drugs are used rationally 27 PAR Seminar, 3 October 2002 WHO - EDM Key elements of drug regulatory system Basic functions in drug regulation (1) Licensing of manufacturers, importers, distributors, wholesale and retail outlets (premises, persons and practices) Marketing authorization for drug products Quality control laboratory testing Provision of drug information and monitoring of drug promotion and advertising Continues……... 28 PAR Seminar, 3 October 2002 WHO - EDM Key elements of drug regulatory system ….continued Basic functions in drug regulation (2) Inspection of manufacturing and distribution channel premises Adverse drug reaction monitoring Authorization of clinical trials Monitoring of drug dispensing and prescribing practices Monitoring of drug utilization and promotion of rational drug use Application of sanctions 29 PAR Seminar, 3 October 2002 WHO - EDM Drug regulation is a multi- faceted activity at the centre of complex interactions Government Manufacturers Products Regulatory authority Experts Prescribers Medicines Importers/Wholesalers/Retailers 30 PAR Seminar, 3 October 2002 Patients/Consumers WHO - EDM Drug regulation is a multi- faceted activity at the centre of complex interactions Government Manufacturers Products Regulatory authority Experts Prescribers Medicines Importers/Wholesalers/Retailers 31 PAR Seminar, 3 October 2002 Patients/Consumers WHO - EDM Drug regulation is a multi- faceted activity at the centre of complex interactions Government Manufacturers Products Regulatory authority Experts Prescribers Medicines Importers/Wholesalers/Retailers 32 PAR Seminar, 3 October 2002 Patients/Consumers WHO - EDM Drug regulation is a multi- faceted activity at the centre of complex interactions Government Manufacturers Products Regulatory authority Experts Prescribers Medicines Importers/Wholesalers/Retailers 33 PAR Seminar, 3 October 2002 Patients/Consumers WHO - EDM Drug regulation is a multi- faceted activity at the centre of complex interactions Government Manufacturers Products Regulatory authority Experts Prescribers Medicines Importers/Wholesalers/Retailers 34 PAR Seminar, 3 October 2002 Patients/Consumers WHO - EDM The challenges: the health system counts on DRA for good, safe, and effective medicines and for fair rules and control on drug trade, information, and use any strategy to improve anything in the pharmaceutcal area involves DRA any problem encountered in the pharmaceutical area has something to do with the DRA 35 PAR Seminar, 3 October 2002 WHO - EDM Country strategies for achieving effective drug regulation 1. Assess drug regulation performance 2. Identify and develop priority functions 3. Provide clear mission and purpose 4. Create a supportive environment 5. Formulate adequate legislation 6. Create appropriate organisational structure 7. Allocate adequate human and financial resources 8. Minimise corruption and conflict of interest 9. Apply appropriate regulatory & enforcement strategies 36 PAR Seminar, 3 October 2002 WHO - EDM Effective regulation depends on the environment adequate consideration is given to the public health value of drugs drug regulation is not fragmented DRA is also accountable to the public drug regulation processes are transparent appropriate sanctions are regularly applied strong, organised public interest groups are incentived to support drug regulatory activities there is freedom of association and information 37 PAR Seminar, 3 October 2002 WHO - EDM PROVISIONS AND PREREQUISITES FOR REGULATORY CONTROL • Political will and commitment: clear, firm, and equitable legislation addressing all the relevant issues and carries appropriate sanctions; financial and other resources that are commensurate with the designated functions; willingness to defend decisions and policies which are to the benefit of public health; support when legislated sanctions are imposed for violations of legislation. 38 PAR Seminar, 3 October 2002 WHO - EDM PROVISIONS AND PREREQUISITES FOR REGULATORY CONTROL • Accountability : means being required to account for one’s conduct and actions, usually to an individual or group but ultimately to the public; field of medicines is highly commercialized, it is characterized by extreme pressures on the DRA and by intensive lobbying from stakeholders at many levels; a system of accountability is essential in managing these tensions. 39 PAR Seminar, 3 October 2002 WHO - EDM PROVISIONS AND PREREQUISITES FOR REGULATORY CONTROL • Mechanisms to ensure accountability: requirement to provide public reports; publication of decisions, processes and policies; mechanism for appeals against DRA decisions; code of conduct for DRA staff and procedure for complaints about actions of DRA and conduct of individual staff; formalized mechanisms for consulting experts; web site with information about the DRA 40 PAR Seminar, 3 October 2002 WHO - EDM PROVISIONS AND PREREQUISITES FOR REGULATORY CONTROL • Staff skills: evaluators should be qualified in pharmacy, clinical pharmacology, medicine or a similar discipline; external expertise should also be available, but authority’s own staff must be capable of understanding and implementing expert advisory body’s recommendations; DRA needs staff to investigate breaches of legislation and initiate action in the courts; a suitable number of competent administrative staff and computer specialists. 41 PAR Seminar, 3 October 2002 WHO - EDM PROVISIONS AND PREREQUISITES FOR REGULATORY CONTROL • Staff number: Number of staff depends on responsibilities to be undertaken. Major determinants of staff numbers: degree to which DRA is prepared to rely on decisions made, and reports prepared, by DRA in other countries; presence of local pharmaceutical industry; number of products to be processed. 42 PAR Seminar, 3 October 2002 WHO - EDM PROVISIONS AND PREREQUISITES FOR REGULATORY CONTROL • Staff training: Routine training for new staff; Scientific skills must be continuously updated to keep pace with drug discovery and development; It is therefore essential for suitable training and practical experience to be offered regularly to the staff concerned. 43 PAR Seminar, 3 October 2002 WHO - EDM PROVISIONS AND PREREQUISITES FOR REGULATORY CONTROL • Premises: Data submitted by applicants should be stored with sufficient security to give the applicants the confidence that they cannot be subject to theft or unauthorized copying. Professional staff whose responsibilities include sustained periods of concentration will perform more efficiently (in terms of output and reliability) in quiet surroundings. 44 PAR Seminar, 3 October 2002 WHO - EDM PROVISIONS AND PREREQUISITES FOR REGULATORY CONTROL Computerized system: • progress of assessment of applications; • premises for which an inspection is due; • date of latest approved product information; • previous decisions taken on same or similar active ingredient & guidance for assessment; • list of marketing authorizations due to expire; • regular reports and lists; • automation of administrative tasks; • alerts for deadlines. 45 PAR Seminar, 3 October 2002 WHO - EDM PROVISIONS AND PREREQUISITES FOR REGULATORY CONTROL Access to the Internet: • information from web sites of other DRAs; • access to technical literature; • up-to-date safety information; • access to web sites of professional associations and NGOs. Own web site: • information on decisions; • regulatory information; • safety information and alerts; • open channel for receiving input from society. 46 PAR Seminar, 3 October 2002 WHO - EDM PROVISIONS AND PREREQUISITES FOR REGULATORY CONTROL Expert advice: • local expertise from universities, research institutes, and health care facilities (all levels); • individuals whose advice is seen by community, health workers and government as authoritative and credible; • fixed-term assignments to reduce risk of dependence on political considerations; • set broad technical policies so that only difficult applications need to be referred; • declaration of “no conflict of interest” before and during activities of the expert advisory body; • reimbursement travel and accommodation plus reasonable remuneration not related to outcome of evaluation. 47 PAR Seminar, 3 October 2002 WHO - EDM PROVISIONS AND PREREQUISITES FOR REGULATORY CONTROL Fees and cost recovery: • for all applications and unrelated to outcome; • certifications & annual fees (support PM activities); • high enough to contribute significantly to effective functioning of DRA without affecting drug price; • conducting services for profit is contrary to purpose and ethic of and distracts from regulatory work; • fees relate to amount of work (fees for generics are lower because they require less assessment work); • low or no fees for vital drugs with limited market, annual fee can be based on annual sales; • fee structure should be transparent. 48 PAR Seminar, 3 October 2002 WHO - EDM PROVISIONS AND PREREQUISITES FOR REGULATORY CONTROL Special access schemes: • allow access to unregistered drug products in special or emergency situations; • avoid de facto marketing. 49 PAR Seminar, 3 October 2002 WHO - EDM PROVISIONS AND PREREQUISITES FOR REGULATORY CONTROL Transparency (1): DRA must answer to both government and the public on: how it fulfils its mission to protect public health; how it prevents corruption; how it prevents decisions unfair to those regulated. 50 PAR Seminar, 3 October 2002 WHO - EDM PROVISIONS AND PREREQUISITES FOR REGULATORY CONTROL Transparency (2): • printed and published policies and procedures; • give reasons for decisions; • transparency is the most efficient way to work: - no time spent clarifying policies and attitudes; - terminology is defined so that the parties use the same terms to mean the same thing; - risk of arbitrary decisions is reduced; - DRA’s image is ‘they implement rules’ rather than ‘they decide’; - ‘competence’ vs ‘bureaucracy’. 51 PAR Seminar, 3 October 2002 WHO - EDM PROVISIONS AND PREREQUISITES FOR REGULATORY CONTROL Written policies: • decisions on individual applications become easier; • examples: when data on bioequivalence are required; when evaluation reports prepared by another DRA will be accepted; which fixed-dose combinations are considered rational; when and from which countries certificates are accepted; what are the acceptable reference sources for drug information. - 52 PAR Seminar, 3 October 2002 WHO - EDM PROVISIONS AND PREREQUISITES FOR REGULATORY CONTROL Written procedures: • • • • staff understand their own role; assessment deadlines are predictable; lines of communication are clear; documentation and reasons for decisions accessible and are easy to identify; • SOP: written procedure giving instructions for performing operations (e.g., reception of applications, individual steps of assessment, issuance of marketing authorization, equipment operation, validation of analytical methods) 53 PAR Seminar, 3 October 2002 WHO - EDM PROVISIONS AND PREREQUISITES FOR REGULATORY CONTROL Example of part of SOP on WHO-type certificate: Decision tree for WHO-type certificate Obtain WHO-type Certificate Issueing authority is in list of reference countries? Yes No Does product have MA in exporting country? Yes No Check if product is exactly the same Review product information and adapt if necessary Review bioequivalence if required Review stability data if required Check if analytical methods are applicable in QC lab 54 PAR Seminar, 3 October 2002 Proceed as if no certificate was submitted WHO - EDM PROVISIONS AND PREREQUISITES FOR REGULATORY CONTROL Quality system: • infrastructure, encompassing organizational structure, procedures, processes, and resources; • organized set of actions necessary to ensure that patients, applicants, and regulators are satisfied that assessment and decisions are within legal requirements and guidance, and consistent with protection and promotion of public health. 55 PAR Seminar, 3 October 2002 WHO - EDM PROVISIONS AND PREREQUISITES FOR REGULATORY CONTROL Quality manual: • contains defined and documented DRA’s policies and objectives; • DRA must ensure that policies are understood and implemented at all levels in the DRA; • describe legal status of all elements of DRA (drug registration, inspectorate, QC lab, etc.); • code of ethics and conduct relating to all DRA activities; • names, qualifications, and terms of reference of the senior staff and other DRA personnel, both internal and external; …………… 56 PAR Seminar, 3 October 2002 WHO - EDM PROVISIONS AND PREREQUISITES FOR REGULATORY CONTROL Quality manual (continued): • training strategies and arrangements for all DRA staff; • organization chart showing lines of authority, responsibility and allocation of functions; • documented procedures for issue, suspension and revocation of marketing authorizations; • list of subcontractors used for specific DRA work and details of the documented procedures for assessing and monitoring their competence; • details of appeals procedures; …………. 57 PAR Seminar, 3 October 2002 WHO - EDM PROVISIONS AND PREREQUISITES FOR REGULATORY CONTROL Quality manual (continued): • procedure for ensuring that complaints are investigated and shortcomings revealed; • list of staff members responsible for investigating complaints and those with authority to take remedial action; • system of records which demonstrates compliance with obligations under national legislation and demonstrates that the quality system is operating satisfactorily. 58 PAR Seminar, 3 October 2002 WHO - EDM The EMEA Quality Manual/Documentation System Structure EMEA Mission Statement & Quality Policy EMEA Policies EMEA Core & Key Tasks (Process Maps/Flowcharts) EMEA SOPs EMEA Forms Standard Documents Templates 59 PAR Seminar, 3 October 2002 WHO - EDM The EMEA Quality Manual/Documentation System Structure EMEA Forms Standard Documents Templates EMEA SOPs EMEA Core & Key Tasks (Process Maps/Flowcharts) EMEA Policies EMEA Mission Statement & Quality Policy 60 PAR Seminar, 3 October 2002 WHO - EDM PROVISIONS AND PREREQUISITES FOR REGULATORY CONTROL • A regulatory “culture” : DRA should lead its staff to independent thinking, impartiality and pride in their work. Everyone should be motivated by a desire to ensure that effective, safe and good-quality drug products are available to the public in adequate quantities and are used rationally. It should be stressed that staff who succumb to favours from outside sources are damaging the reputation of the whole organization, including that of their colleagues. 61 PAR Seminar, 3 October 2002 WHO - EDM Drug legislation and regulation Rationale for state role Key elements of drug legislation Key elements of drug regulatory system Drug regulation and public health 62 PAR Seminar, 3 October 2002 WHO - EDM World Health Assembly resolution 52.19 24 May 1999: WHO’s Revised Drug Strategy URGES Member States: (1) to reaffirm their commitment to …… taking all necessary concrete measures in order to ensure equitable access to essential drugs; (2) to ensure that public health interests are paramount in pharmaceutical and health policies; (3) to explore and review their options under relevant international agreements, including trade agreements, to safeguard access to essential drugs; 63 PAR Seminar, 3 October 2002 WHO - EDM World Health Assembly resolution 52.19 24 May 1999: WHO’s Revised Drug Strategy Implications for drug regulatory authorities: - put public health as first priority of regulatory system development strategy and decisions - contribute to develop market of good quality, safe, effective,and affordable drugs - improve drug assessment and market control Improve regulatory system's capacity to meet needs of health professionals and public 64 PAR Seminar, 3 October 2002 WHO - EDM Access to quality drugs: To ensure access to quality drugs there is no better strategy than building a reliable and effective national drug regulatory authority 65 PAR Seminar, 3 October 2002 WHO - EDM Drug regulation and public health Good regulatory practice requires: Mission and objectives clearly stated Possibility to assess attainment of objectives Procedures and outcomes transparent to applicants, health professionals, and public Arguments used to reach decision accessible to the public Reasonable duration of assessment without compromising quality, safety & efficacy 9th ICDRA 29/4/1999 66 PAR Seminar, 3 October 2002 WHO - EDM Drug regulation and public health Good regulatory practice requires: Expedite review for orphan and outstanding public-health-value drugs Accountability to government, those regulated, and the public Personnel adequately trained, highly qualified, of high integrity Human resource development programme 9th ICDRA 29/4/1999 67 PAR Seminar, 3 October 2002 WHO - EDM Drug regulation and public health Good regulatory practice requires: Mechanisms for appeal and for citizens' complaints Access to appropriate knowledge and technology Citizens are provided with accurate and appropriate drug information Mechanisms to ensure quality of operating procedures 9th ICDRA 29/4/1999 68 PAR Seminar, 3 October 2002 WHO - EDM Drug regulation and public health No national authority meets all criteria, ......but some are closer than others All want to improve, .... but some are much better placed 69 PAR Seminar, 3 October 2002 WHO - EDM Big gaps exist TECHNICAL COMPLEXITY OF REQUIREMENTS ICH IC LDC 70 PAR Seminar, 3 October 2002 WHO - EDM Thousands of highly qualified professionals Thousands of highly qualified external experts Virtually unlimited access to the most sophisticated technology and knowledge 71 PAR Seminar, 3 October 2002 WHO - EDM Gaps also exist between nonICH counties: e.g. between newer and older members of ASEAN Harmonisation Mutual understanding, ...or one-way understanding? 72 PAR Seminar, 3 October 2002 WHO - EDM No importable models: ..approach to drug regulation must be attuned to available resources... ...problems in establishing drug control have too often resulted from the adaptation of provisions successful elsewhere but of a complexity that precludes their effective implementation in the country of adoption... WHO Expert Committee on Specifications for Pharmaceutical Preparations, TSR 790, 1990 73 PAR Seminar, 3 October 2002 WHO - EDM Drug regulation and public health Setting priorities based on available resources: ensure effective market control: establish list of authorized/marketed products, strengthen inspection of distribution channels (if appropriate limit number of entry points for imported drugs and number of distributors), establish adequate sanctions for violators; establish GMP requirement and inspections; identify ‘reference’ DRAs for reports, decisions, drug information, safety alerts; focus on regulation and control of generics; build collaboration with academic and research intitutions and NGOs to address drug selection and rational use. 74 PAR Seminar, 3 October 2002 WHO - EDM Huge differences in regulatory environment do exist. What can regulators do? Wait for political will, improved legislation, more resources to appear ? Or rather try to improve regulatory work with current environment and resources in order to maximise its potential for improving public health? 75 PAR Seminar, 3 October 2002 WHO - EDM